Precigen (NASDAQ:PGEN) Rating Increased to Strong-Buy at Zacks Research

Posted by Stanley Muller on Aug 7th, 2026

Zacks Research upgraded shares of Precigen (NASDAQ:PGEN – Free Report) from a hold rating to a strong-buy rating in a research report report published on Wednesday,Zacks.com reports.

Several other research analysts have also commented on the company. Citigroup restated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Citizens Jmp boosted their price objective on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Wall Street Zen cut Precigen from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Finally, HC Wainwright lifted their target price on Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.50.

View Our Latest Analysis on Precigen

Precigen Price Performance

Precigen stock opened at $6.91 on Wednesday. The company’s 50 day simple moving average is $5.17 and its 200-day simple moving average is $4.48. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of -6.64 and a beta of 1.02. Precigen has a 1 year low of $1.70 and a 1 year high of $7.23. The company has a debt-to-equity ratio of 2.15, a quick ratio of 4.12 and a current ratio of 4.58.

Precigen (NASDAQ:PGEN – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The firm had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. The company’s revenue was up 6322.7% compared to the same quarter last year. As a group, equities research analysts expect that Precigen will post -0.02 earnings per share for the current year.

Insider Buying and Selling at Precigen

In other Precigen news, CFO Harry Jr. Thomasian sold 171,429 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.53, for a total value of $948,002.37. Following the completion of the transaction, the chief financial officer owned 354,535 shares of the company’s stock, valued at $1,960,578.55. This trade represents a 32.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Donald P. Lehr sold 29,131 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total transaction of $127,011.16. Following the completion of the transaction, the insider owned 755,461 shares of the company’s stock, valued at approximately $3,293,809.96. This trade represents a 3.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 956,500 shares of company stock worth $5,248,371. 41.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp increased its stake in shares of Precigen by 141.1% during the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock worth $45,248,000 after buying an additional 6,335,033 shares during the period. SymBiosis Capital Partners LLC purchased a new position in Precigen in the fourth quarter worth approximately $12,540,000. Bank of America Corp DE grew its holdings in Precigen by 201.1% during the 3rd quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock worth $8,245,000 after acquiring an additional 1,673,731 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Precigen by 196.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,173,933 shares of the biotechnology company’s stock worth $9,087,000 after acquiring an additional 1,440,446 shares in the last quarter. Finally, Occam Crest Management LP increased its position in shares of Precigen by 29.6% in the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after purchasing an additional 799,339 shares during the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Precigen

Here are the key news stories impacting Precigen this week:

Positive Sentiment: Strong Q2 performance and profitability: Precigen reported that PAPZIMEOS revenue reached $53.1 million in the second quarter, roughly doubling sequentially. The company also achieved profitability, while earnings-call coverage highlighted a 145% increase in revenue. These results support the view that PAPZIMEOS is becoming a meaningful commercial product. Precigen Q2 2026 Earnings Call Highlights
Positive Sentiment: Regulatory and commercial catalysts: FDA approval of PAPZIMEOS for recurrent respiratory papillomatosis, along with seven years of U.S. market exclusivity, strengthens the product’s revenue outlook. Potential European approval and expansion of Precigen’s AdenoVerse Immunotherapy platform—including PRGN-2009—could provide additional growth opportunities. Precigen Strong Buy and PAPZIMEOS Outlook
Positive Sentiment: Analyst estimates moved higher: HC Wainwright reiterated its Buy rating and $18 price target, raising its FY2027 EPS forecast to $0.44 from $0.34. Estimates for Q4 2026 and each quarter of 2027 were also increased, while the FY2030 forecast rose to $1.49 from $1.44. These revisions signal greater confidence in the company’s earnings trajectory. HC Wainwright Reiterates Buy Rating for Precigen
Neutral Sentiment: Unusually large options activity attracted attention, but the available report does not identify whether the transactions were bullish or bearish. Precigen Unusually Large Options Trading
Negative Sentiment: One forecast was trimmed: HC Wainwright reduced its FY2028 EPS estimate slightly to $0.71 from $0.72, a minor offset to the broader upward revisions.

About Precigen

(Get Free Report)

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.